Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

System Xc- Antiporter Inhibitors: Azo-Linked Amino-Naphthyl-Sulfonate Analogues of Sulfasalazine.

Nehser M, Dark J, Schweitzer D, Campbell M, Zwicker J, Hitt DM, Little H, Diaz-Correa A, Holley DC, Patel SA, Thompson CM, Bridges RJ.

Neurochem Res. 2019 Nov 21. doi: 10.1007/s11064-019-02901-6. [Epub ahead of print]

PMID:
31754956
2.

CFTR modulator theratyping: Current status, gaps and future directions.

Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL.

J Cyst Fibros. 2019 Jan;18(1):22-34. doi: 10.1016/j.jcf.2018.05.004. Epub 2018 Jun 20. Review.

3.

Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator and Drugs: Insights from Cellular Trafficking.

Bridges RJ, Bradbury NA.

Handb Exp Pharmacol. 2018;245:385-425. doi: 10.1007/164_2018_103. Review.

PMID:
29460152
4.

Restoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice.

Zeng M, Szymczak M, Ahuja M, Zheng C, Yin H, Swaim W, Chiorini JA, Bridges RJ, Muallem S.

Gastroenterology. 2017 Oct;153(4):1148-1159. doi: 10.1053/j.gastro.2017.06.011. Epub 2017 Jun 19.

5.

Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.

Xue X, Mutyam V, Thakerar A, Mobley J, Bridges RJ, Rowe SM, Keeling KM, Bedwell DM.

Hum Mol Genet. 2017 Aug 15;26(16):3116-3129. doi: 10.1093/hmg/ddx196.

6.

Fatty Acid Cysteamine Conjugates as Novel and Potent Autophagy Activators That Enhance the Correction of Misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).

Vu CB, Bridges RJ, Pena-Rasgado C, Lacerda AE, Bordwell C, Sewell A, Nichols AJ, Chandran S, Lonkar P, Picarella D, Ting A, Wensley A, Yeager M, Liu F.

J Med Chem. 2017 Jan 12;60(1):458-473. doi: 10.1021/acs.jmedchem.6b01539. Epub 2016 Dec 23.

PMID:
27976892
7.

Evidence against resveratrol as a viable therapy for the rescue of defective ΔF508 CFTR.

Jai Y, Shah K, Bridges RJ, Bradbury NA.

Biochim Biophys Acta. 2015 Nov;1850(11):2377-84. doi: 10.1016/j.bbagen.2015.08.020. Epub 2015 Sep 2.

8.

The development of benzo- and naphtho-fused quinoline-2,4-dicarboxylic acids as vesicular glutamate transporter (VGLUT) inhibitors reveals a possible role for neuroactive steroids.

Carrigan CN, Patel SA, Cox HD, Bolstad ES, Gerdes JM, Smith WE, Bridges RJ, Thompson CM.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):850-4. doi: 10.1016/j.bmcl.2013.12.086. Epub 2013 Dec 25.

9.

Novel di-aryl-substituted isoxazoles act as noncompetitive inhibitors of the system Xc(-) cystine/glutamate exchanger.

Newell JL, Keyari CM, McDaniel SW, Diaz PJ, Natale NR, Patel SA, Bridges RJ.

Neurochem Int. 2014 Jul;73:132-8. doi: 10.1016/j.neuint.2013.11.012. Epub 2013 Dec 11.

PMID:
24333322
10.

Microwave accelerated synthesis of isoxazole hydrazide inhibitors of the system xc- transporter: Initial homology model.

Matti AA, Mirzaei J, Rudolph J, Smith SA, Newell JL, Patel SA, Braden MR, Bridges RJ, Natale NR.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5931-5. doi: 10.1016/j.bmcl.2013.08.080. Epub 2013 Aug 27.

11.

Effect of apical hyperosmotic sodium challenge and amiloride on sodium transport in human bronchial epithelial cells from cystic fibrosis donors.

Rasgado-Flores H, Krishna Mandava V, Siman H, Van Driessche W, Pilewski JM, Randell SH, Bridges RJ.

Am J Physiol Cell Physiol. 2013 Dec 1;305(11):C1114-22. doi: 10.1152/ajpcell.00166.2013. Epub 2013 Aug 28.

12.

The 2012 SAGE wait times program: Survey of Access to GastroEnterology in Canada.

Leddin D, Armstrong D, Borgaonkar M, Bridges RJ, Fallone CA, Telford JJ, Chen Y, Colacino P, Sinclair P.

Can J Gastroenterol. 2013 Feb;27(2):83-9.

13.

Development and validation of a nurse-assessed patient comfort score for colonoscopy.

Rostom A, Ross ED, Dubé C, Rutter MD, Lee T, Valori R, Bridges RJ, Pontifex D, Webbink V, Rees C, Brown C, Whetter DH, Kelsey SG, Hilsden RJ.

Gastrointest Endosc. 2013 Feb;77(2):255-61. doi: 10.1016/j.gie.2012.10.003.

PMID:
23317691
14.

Mechanisms of bicarbonate secretion: lessons from the airways.

Bridges RJ.

Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a015016. doi: 10.1101/cshperspect.a015016. Review.

15.
16.
17.
18.

Coupling biomarkers and drug action for neurodegenerative disease therapies: does the nose know?: Commentary on Sattler et al.: human nasal olfactory epithelium as a dynamic marker for CNS therapy development.

Cardozo-Pelaez F, Bridges RJ.

Exp Neurol. 2012 Jun;235(2):508-12. doi: 10.1016/j.expneurol.2012.03.006. Epub 2012 Mar 20. No abstract available.

PMID:
22465461
19.

Sulfasalazine for brain cancer fits.

Sontheimer H, Bridges RJ.

Expert Opin Investig Drugs. 2012 May;21(5):575-8. doi: 10.1517/13543784.2012.670634. Epub 2012 Mar 12.

20.

Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences.

Mendoza JL, Schmidt A, Li Q, Nuvaga E, Barrett T, Bridges RJ, Feranchak AP, Brautigam CA, Thomas PJ.

Cell. 2012 Jan 20;148(1-2):164-74. doi: 10.1016/j.cell.2011.11.023.

21.

Development and implementation of a comprehensive quality assurance program at a community endoscopy facility.

Hilsden RJ, Rostom A, Dubé C, Pontifex D, McGregor SE, Bridges RJ.

Can J Gastroenterol. 2011 Oct;25(10):547-54.

22.

Increased excitatory amino acid transport into murine prion protein knockout astrocytes cultured in vitro.

Pathmajeyan MS, Patel SA, Carroll JA, Seib T, Striebel JF, Bridges RJ, Chesebro B.

Glia. 2011 Nov;59(11):1684-94. doi: 10.1002/glia.21215. Epub 2011 Jul 15.

23.

Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-).

Ahmed SK, Etoga JL, Patel SA, Bridges RJ, Thompson CM.

Bioorg Med Chem Lett. 2011 Jul 15;21(14):4358-62. doi: 10.1016/j.bmcl.2011.05.018. Epub 2011 May 14.

24.

Regulation of the system x(C)- cystine/glutamate exchanger by intracellular glutathione levels in rat astrocyte primary cultures.

Seib TM, Patel SA, Bridges RJ.

Glia. 2011 Oct;59(10):1387-401. doi: 10.1002/glia.21176. Epub 2011 May 17.

PMID:
21590811
25.

System xc⁻ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS.

Bridges RJ, Natale NR, Patel SA.

Br J Pharmacol. 2012 Jan;165(1):20-34. doi: 10.1111/j.1476-5381.2011.01480.x.

26.

Looking forward: the Canadian Association of Gastroenterology strategic plan.

Bridges RJ, Morgan D, Sinclair P, Sadowski D.

Can J Gastroenterol. 2011 Apr;25(4):183-5. No abstract available.

27.

Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening.

Kalid O, Mense M, Fischman S, Shitrit A, Bihler H, Ben-Zeev E, Schutz N, Pedemonte N, Thomas PJ, Bridges RJ, Wetmore DR, Marantz Y, Senderowitz H.

J Comput Aided Mol Des. 2010 Dec;24(12):971-91. doi: 10.1007/s10822-010-9390-0. Epub 2010 Oct 26.

28.

Functional expression, purification and high sequence coverage mass spectrometric characterization of human excitatory amino acid transporter EAAT2.

Ye R, Rhoderick JF, Thompson CM, Bridges RJ.

Protein Expr Purif. 2010 Nov;74(1):49-59. doi: 10.1016/j.pep.2010.04.006. Epub 2010 Apr 22.

29.

Summary of the Canadian Association of Gastroenterology 2004 strategic plan.

Bridges RJ, Paterson WG, Sinclair P, Morgan DG.

Can J Gastroenterol. 2010 Mar;24(3):164-72. English, French. No abstract available.

30.

Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x(c)(-) over the vesicular glutamate transporter.

Etoga JL, Ahmed SK, Patel S, Bridges RJ, Thompson CM.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2680-3. doi: 10.1016/j.bmcl.2009.10.020. Epub 2009 Oct 12.

31.

Survey of access to gastroenterology in Canada: the SAGE wait times program.

Leddin D, Bridges RJ, Morgan DG, Fallone C, Render C, Plourde V, Gray J, Switzer C, McHattie J, Singh H, Walli E, Murray I, Nestel A, Sinclair P, Chen Y, Irvine EJ.

Can J Gastroenterol. 2010 Jan;24(1):20-5.

32.

Isoxazole analogues bind the system xc- transporter: structure-activity relationship and pharmacophore model.

Patel SA, Rajale T, O'Brien E, Burkhart DJ, Nelson JK, Twamley B, Blumenfeld A, Szabon-Watola MI, Gerdes JM, Bridges RJ, Natale NR.

Bioorg Med Chem. 2010 Jan 1;18(1):202-13. doi: 10.1016/j.bmc.2009.11.001. Epub 2009 Nov 10.

33.

Dynasore inhibits removal of wild-type and DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) from the plasma membrane.

Young A, Gentzsch M, Abban CY, Jia Y, Meneses PI, Bridges RJ, Bradbury NA.

Biochem J. 2009 Jul 15;421(3):377-85. doi: 10.1042/BJ20090389.

PMID:
19442237
34.

Report from the Canadian Association of Gastroenterology Board.

Bridges RJ.

Can J Gastroenterol. 2009 Mar;23(3):161-7.

35.

Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease.

Coote K, Atherton-Watson HC, Sugar R, Young A, MacKenzie-Beevor A, Gosling M, Bhalay G, Bloomfield G, Dunstan A, Bridges RJ, Sabater JR, Abraham WM, Tully D, Pacoma R, Schumacher A, Harris J, Danahay H.

J Pharmacol Exp Ther. 2009 May;329(2):764-74. doi: 10.1124/jpet.108.148155. Epub 2009 Feb 3.

PMID:
19190233
36.

Synthesis and preliminary pharmacological evaluation of novel derivatives of L-beta-threo-benzylaspartate as inhibitors of the neuronal glutamate transporter EAAT3.

Mavencamp TL, Rhoderick JF, Bridges RJ, Esslinger CS.

Bioorg Med Chem. 2008 Aug 15;16(16):7740-8. doi: 10.1016/j.bmc.2008.07.001. Epub 2008 Jul 8.

37.

Ethyl 4-{1-[(2,4-dinitro-phen-yl)hydrazono]eth-yl}-5-(2-naphthyl-methoxy-meth-yl)isoxazole-3-carboxyl-ate.

Natale NR, Szabon-Watola MI, Twamley B, Bridges RJ, Patel S, Rajale T.

Acta Crystallogr Sect E Struct Rep Online. 2008 Dec 17;65(Pt 1):o144-5. doi: 10.1107/S1600536808041901.

38.

A segment of gamma ENaC mediates elastase activation of Na+ transport.

Adebamiro A, Cheng Y, Rao US, Danahay H, Bridges RJ.

J Gen Physiol. 2007 Dec;130(6):611-29. Epub 2007 Nov 12.

39.

Regional distribution of sodium-dependent excitatory amino acid transporters in rat spinal cord.

Queen SA, Kesslak JP, Bridges RJ.

J Spinal Cord Med. 2007;30(3):263-71.

40.

Electrogenic bicarbonate secretion by prairie dog gallbladder.

Moser AJ, Gangopadhyay A, Bradbury NA, Peters KW, Frizzell RA, Bridges RJ.

Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1683-94. Epub 2007 Mar 15.

41.

Methods for detecting internalized, FM 1-43 stained particles in epithelial cells and monolayers.

Bertrand CA, Laboisse C, Hopfer U, Bridges RJ, Frizzell RA.

Biophys J. 2006 Nov 15;91(10):3872-83. Epub 2006 Aug 25.

42.

Identification and membrane localization of electrogenic sodium bicarbonate cotransporters in Calu-3 cells.

Kreindler JL, Peters KW, Frizzell RA, Bridges RJ.

Biochim Biophys Acta. 2006 Jul;1762(7):704-10. Epub 2006 Jun 17.

43.

Membrane capacitance and conductance changes parallel mucin secretion in the human airway epithelium.

Danahay H, Atherton HC, Jackson AD, Kreindler JL, Poll CT, Bridges RJ.

Am J Physiol Lung Cell Mol Physiol. 2006 Mar;290(3):L558-69. Epub 2005 Oct 14.

44.

Endogenous protease activation of ENaC: effect of serine protease inhibition on ENaC single channel properties.

Adebamiro A, Cheng Y, Johnson JP, Bridges RJ.

J Gen Physiol. 2005 Oct;126(4):339-52.

45.

The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3.

Esslinger CS, Agarwal S, Gerdes J, Wilson PA, Davis ES, Awes AN, O'Brien E, Mavencamp T, Koch HP, Poulsen DJ, Rhoderick JF, Chamberlin AR, Kavanaugh MP, Bridges RJ.

Neuropharmacology. 2005 Nov;49(6):850-61. Epub 2005 Sep 23.

PMID:
16183084
46.

The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes.

Bridges RJ, Esslinger CS.

Pharmacol Ther. 2005 Sep;107(3):271-85. Epub 2005 Apr 14. Review.

PMID:
16112332
47.

Inhibitor of the glutamate vesicular transporter (VGLUT).

Thompson CM, Davis E, Carrigan CN, Cox HD, Bridges RJ, Gerdes JM.

Curr Med Chem. 2005;12(18):2041-56. Review.

PMID:
16101493
48.

Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract.

Kreindler JL, Jackson AD, Kemp PA, Bridges RJ, Danahay H.

Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L894-902. Epub 2004 Dec 30.

49.

The Lathyrus excitotoxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid is a substrate of the L-cystine/L-glutamate exchanger system xc-.

Warren BA, Patel SA, Nunn PB, Bridges RJ.

Toxicol Appl Pharmacol. 2004 Oct 15;200(2):83-92.

PMID:
15476861
50.

Transepithelial fluctuation analysis of chloride secretion.

Singh AK, Schultz BD, van Driessche W, Bridges RJ.

J Cyst Fibros. 2004 Aug;3 Suppl 2:127-32.

Supplemental Content

Loading ...
Support Center